Pharmaceutical Glass Packaging Market Size, Share & Trends Report

Pharmaceutical Glass Packaging Market Size, Share & Trends Analysis Report By Product (Vials, Ampoules, Cartridges & Syringes), By Drug Type (Generic, Branded, Biologic), And Segment Forecasts, 2018 - 2025

  • Published Date: May, 2018
  • Base Year for Estimate: 2016
  • Report ID: GVR-2-68038-175-7
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016
  • Number of Pages: 258

Industry Outlook

The global pharmaceutical glass packaging market size was estimated at USD 12.84 billion in 2016. It is projected to witness a CAGR of 6.3% from 2017 to 2025. Increasing sales volume of low-cost generic drugs and a well-established supply chain of raw materials are among the key trends stoking market growth. Glass is completely recyclable and doesn’t lose its purity or quality when recycled.

U.S. pharmaceutical glass packaging market

Glass exhibits properties that make it a suitable material for packaging pharmaceutical products. For instance, glass containers offer better protection to drug formulation as they are impermeable to air & moisture and resistant to chemicals, thus preventing the drug from contamination or denaturing. Furthermore, inert nature of the product increases the stability of drug by avoiding interaction between drug molecules and environmental particles, thus preventing its degradation.

Factors such as overall increase in the consumption of generic drugs and growing access to healthcare services are cumulatively presenting new opportunities for pharmaceutical companies. Emerging economies such as China, India, and Brazil have been witnessing considerable growth in the pharmaceutical industry, which is anticipated to provide an upthrust to the market.

Glass has been traditionally used for packaging of pharmaceutical parenteral products. However, it is estimated to face a strong competition from the plastic industry owing to issues such as its tendency to break easily, susceptibility to particulate contamination, delamination, and interaction with drug products, which are most likely to harm a patient and cause contamination.

The industry is constantly being driven by extensive R&D, conducted by key global players such as Corning Inc.; Gerresheimer AG; Schott AG; Stevanato Group; and West Pharmaceutical Services, Inc. For instance, in July 2017, Corning Inc. in collaboration with Merck and Pfizer developed Valor aluminosilicate glass, which can be used as a replacement for conventional Type I alkali borosilicate glass. This was aimed at helping manufacturers to overcome shortcomings of the latter such as breakage, variation in hydrolytic performance, and delamination. Introduction of such products can help in improving drug efficacy.

Factors such as growing population, increasing life expectancy, and rising disposable income are projected to provide packaging companies with attractive opportunities in the healthcare sector in the coming years. BRICMT (Brazil, Russia, India, China, Mexico, and Turkey) countries have shown strong economic growth in the past few years. These countries are transforming into markets that are comparable in size and nature to their mature western counterparts.

Product Insights

On the basis of product, the market can be segmented into vials, bottles, cartridges & syringes, and ampoules. Vials are further divided into small (<30 ml) and large (>30 ml). Similarly, the bottles segment can be bifurcated into small (<1000 ml) and large (>1000 ml). Bottles held more than 35.0% of the overall revenue in 2016.Small-sized bottles aiming for drug packaging are relatively more popular than the large ones. These are mostly used for packaging of oral liquid, drops, and solid, whereas large bottles aregenerally used for packaging of infusion & transfusion bottles as well as reagents.

In terms of revenue, vials represented more than 30.0% of the global market in 2016. This is backed by the fact that most of the manufacturers are investing in vials, which are aimed at increasing shelf life of drugs. For instance, in March 2017, Gerresheimer AG introduced its Gx RTF vials with the Ompi EZ-Fill packaging technology combining the company’s core competencies of molding vials from glass tubing and ready-to-fill process for prefilled syringes. Vials are being increasingly used in the pharmaceutical industry for collection of biological samples.

Ampoules is the most promising segment, which is poised to register a CAGR of 8.4%, in terms of revenue, from 2017 to 2025. They are widely used in packaging of injection drugs. Ampoules are a type of primary packaging for pharmaceutical drugs, where the drug comes only in contact with the inert glass material, which is also tamper-proof.

Prefilled syringes are being increasingly preferred to reduce the risk of contamination of biologics, which is expected to fuel its demand over the forecast period. Manufacturers have been enhancing their capabilities to improve the quality of prefilled syringes in their respective product portfolio. For instance, Gerresheimer AG developed a metal-free 1 ml Gx RTF long luer-lock syringe in which the cone is made of a special ceramic material instead of conventional tungsten, which can cause metal contamination.

Drug Type Insights

The market size for generic drugs was valued at approximately USD 235 billion in 2016. Non-branded generics accounted for a revenue share of 34.0% whereas branded generics accounted for a revenue share of 66.0% in the same year. Demand for branded generic drugs is anticipated to remain strong in Asian countries over the coming years and physicians remain an important stakeholder in driving drug sales. Demand for glass packaging in generic drugs is estimated to progress at a CAGR of 7.4%, in terms of revenue, from 2017 to 2025.

Global pharmaceutical glass packaging market

North America has a relatively larger market for branded drugs as compared to rest of the world. Major manufacturers of branded drugs in the region are Johnson & Johnson; Pfizer; Sanofi-Aventis (Sanofi Pasteur); Merck (Schering-Plough Canada Inc.); and GlaxoSmithKline Inc.

The revenue generated by the branded drugs segment in 2016 was close to USD 2.36 billion and is projected to register a CAGR of 4.0% during the forecast period.

Rising susceptibility to diseases is creating an upswing in the demand for biologics owing to their therapeutic benefits, which is encouraging several pharmaceutical companies worldwide to invest in them. Biologic drugs are costly and are difficult to develop. This gives them the advantage over other drug products in terms of differentiation and higher pricing/profitability. Surging use of plastic in packaging of biologics is likely to restrain the demand for glass packaging over the forecast period.

Regional Insights

In terms of region, North America dominated the pharmaceutical glass packaging market and accounted for a revenue share of close to 38.0% in 2016. The U.S. is the world’s largest and the most influential pharmaceutical market, which is projected to present attractive opportunities for glass packaging companies.

Launch of several initiatives in Europe, such as the PRIME (Priority Medicine) scheme, which is aimed at increasing the support for medicines, is set to offer a huge advantage to the therapeutics industry.In 2016, Europe accounted for 21.5% of the world pharmaceutical market, in terms of sales.

Asia Pacific will be the most promising regional market during the forecast period. China, Japan, South Korea, and India are the sights of high growth rates in Asia Pacific. Furthermore, countries such as Australia and China are focusing on forming trade agreements to boost their export potential within the region.

Tremendous growth in population coupled with a steady economic growth is contributing to the growth of the regional market.Increasing disposable income of middle-class population is benefitting the growth of the manufacturing sector in Asia Pacific, thus driving the market.

Pharmaceutical Glass Packaging Market Share Insights

Companies such as Gerresheimer AG, Corning Incorporated, and Schott AG are pioneers of a majority of research initiatives undertaken in the market. These companies are engaged in introducing new technologies and products to cater to drug manufacturing companies.

In Feb 2017, Gerresheimer AG collaborated with West Pharmaceuticals and introduced the Gx Innosafe safety system for glass syringes with an integrated passive safety system. This system avoids inadvertent needle prick injuries, precludes reuse, and is optimized both for the pharma industry production workflows and for easy and intuitive use by medical personnel. The company has installed this safety system like a standard needle shield on its Gx RTF syringes.

Other companies present in the industry include Nipro Corporation; SGD Pharma; Stevanato Group S.p.A.; West Pharmaceutical Services, Inc.; Piramal Glass; Şişecam Group; and Stölzle-Oberglas GmbH.

Report Scope

Attribute

Details

Base year for estimation

2016

Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2025

Market representation

Revenue in USD Million & CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Central & South America, MEA

Report coverage      

Revenue forecast, company share, competitive landscape, growth factors and trends

Country Scope

U.S., Germany, U.K., France, Spain, Italy, China, India, Japan, South Korea, Brazil

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth at global, regional, & country levels, and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global pharmaceutical glass packaging market report on the basis of product, drug type, and region:

  • Product Outlook (Revenue, USD Million, 2014 - 2025)

    • Vials

      • Small vials (<30ml)

      • Large vials (>30ml)

    • Bottles

      • Small Bottles (< 1000 ml)

      • Large Bottles (> 1000 ml)

    • Ampoules

    • Cartridges & Syringes

  • Drug Type Outlook (Revenue, USD Million), 2014 - 2025

    • Generic

    • Branded

    • Biologic

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

    • Europe

      • Germany

      • U.K.

      • France

      • Spain

      • Italy

    • Asia Pacific

      • China

      • India

      • Japan

      • South Korea

    • Central & South America

      • Brazil

    • Middle East & Africa

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,950
Multi User (2-5) - $5,950
Enterprise Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified